Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 7:17:175-188.
doi: 10.2147/ORR.S521832. eCollection 2025.

A Review on Bone Tumor Management: Cutting-Edge Strategies in Bone Grafting, Bone Graft Substitute, and Growth Factors for Defect Reconstruction

Siwat Sakdejayont  1 , Thanapon Chobpenthai  1 , Ploy Suksirivecharuk  1 , I-Fan Ninatkiattikul  1 , Thanate Poosiripinyo  2
Affiliations
Review

A Review on Bone Tumor Management: Cutting-Edge Strategies in Bone Grafting, Bone Graft Substitute, and Growth Factors for Defect Reconstruction

Siwat Sakdejayont et al. Orthop Res Rev. .

Abstract

Bone tumors present complex challenges in orthopaedic oncology, requiring precise management strategies to restore skeletal integrity and function with minimal morbidity. Traditional autologous bone grafting has been the gold standard due to its osteogenic, osteoconductive, and osteoinductive properties. However, limitations such as donor site morbidity and graft availability have prompted the development of alternative approaches.This review evaluates contemporary approaches in bone tumor management, focusing on advancements in bone grafting techniques, bone graft substitutes (eg, ceramics, polymers, bioactive materials), and growth factor-based therapies. The efficacy and safety of these substitutes are compared with autografts, examining their potential benefits and drawbacks.Recent innovations in bone graft substitutes show promise in overcoming autograft limitations. Ceramic, polymer, and bioactive materials offer diverse properties that may enhance bone regeneration. Growth factor-based therapies, including bone morphogenetic proteins (BMPs) and vascular endothelial growth factor (VEGF), have revolutionized bone healing by stimulating osteogenesis and angiogenesis.

Keywords: Bone tumors; bone graft; defect reconstruction; growth factor; tumor management.

Plain language summary

The review compares efficacy and safety of bone graft substitutes with traditional autografts, highlighting their potential benefits and challenges, thus helping clinicians choose the most suitable option for bone tumor management.Autologous bone grafting remains the gold standard; its limitations—such as donor site morbidity and limited graft availability—have driven the development of alternative approaches like bone graft substitutes and growth factor-based therapies.Advances in materials such as ceramics, polymers, and bioactive substances offer promising solutions for bone defect reconstruction, providing enhanced properties for bone regeneration and overcoming the shortcomings of autografts.Growth factor therapies, including Bone Morphogenetic Proteins (BMPs) and Vascular Endothelial Growth Factor (VEGF), transform bone healing by stimulating osteogenesis and angiogenesis, improving the recovery and function of the affected bone.Integrating bone graft substitutes and growth factor therapies, there is significant potential to improve clinical outcomes in orthopaedic oncology, offering more effective bone defect reconstruction and enhanced quality of life for patients.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Schematic illustration demonstrating a distinctive bone fracture healing mechanism, key biological proceedings, and cellular paths at various stages.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bădilă AE, Rădulescu DM, Niculescu AG, Grumezescu AM, Rădulescu M, Rădulescu AR. Recent advances in the treatment of bone metastases and primary bone tumors: an up-to-date review. Cancers. 2021;13(16):4229. - PMC - PubMed
    1. Sitarski AM, Fairfield H, Falank C, Reagan MR. 3D tissue engineered in vitro models of cancer in bone. ACS Biomater Sci Eng. 2018;4(2):324–336. doi:10.1021/acsbiomaterials.7b00097 - DOI - PMC - PubMed
    1. Tanaka K, Ozaki T. New TNM classification (AJCC eighth edition) of bone and soft tissue sarcomas: JCOG bone and soft tissue tumor study group. Jpn J Clin Oncol. 2019;49(2):103–107. doi:10.1093/jjco/hyy157 - DOI - PubMed
    1. Sivapathasundharam B, Biswas PG, Preethi S. The world health organization classification of odontogenic and maxillofacial bone tumors: an appraisal. J Oral Maxillofac Pathol. 2019;23(2):178–186. doi:10.4103/jomfp.JOMFP_211_19 - DOI - PMC - PubMed
    1. Roden RD. Principles of bone grafting. Oral Maxillofac Surg Clin North Am. 2010;22(3):295–300. doi:10.1016/j.coms.2010.06.001 - DOI - PubMed

LinkOut - more resources